Sign in
Taking people in United StatesPhase 3

A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia

Key facts

Who runs it
Crinetics Pharmaceuticals Inc.
Where
Ann Arbor, Atlanta, Aurora, Baltimore, Charlottesville, Chicago, Dallas, Gainesville, Los Angeles, Milwaukee, Minneapolis, New Brunswick, Philadelphia, Pittsburgh, and Rochester, United StatesSee the 15 sitesAlso in 14 other countries, 63 sites
Status
Recruiting
Phase
Phase 3
People taking part
150 people, planned
Started
11 Dec 2025
Expected to end
May 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Atumelnant
  • Placebo
Record updated
10 November 2026

Who can take part

Age
18 years to 74 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Male or female, between ≥18 to <75 years of age at the time of signing the ICF
  • Willing and able to understand and adhere to the study procedures as specified in the protocol and comply with the study treatment
  • Have classic CAH due to 21-OHD confirmed by the Investigator
  • Participants with Visit 2 levels of morning serum A4 as follows:; A4 >ULN and treated with <11 mg/m2/day (physiologic) GC doses; OR normal A4 (>0.5xULN to ≤1xULN) and treated with ≥14 mg/m2/day GC doses; OR A4 >ULN and treated with ≥11 mg/m2/day GC doses
  • On a stable (defined as no dose change of >5 mg/day hydrocortisone equivalent within 2 months prior to Screening) regimen of GC replacement (e.g., hydrocortisone, prednisolone, prednisone, methylprednisolone, meprednisone, dexamethasone, cortisone acetate) at the time of informed consent
  • If treated with mineralocorticoids (fludrocortisone), the dose should be stable for at least 1 month prior to Screening without orthostatic hypotension, and with serum sodium and potassium in the normal range
  • If on estrogen therapy (any route), the dose must be stable for at least 3 months prior to Screening

Who cannot take part

  • Concomitant mental condition rendering him/her unable to understand the nature, scope, and possible consequences of the study, and/or evidence of poor compliance with medical instructions
  • Use of atumelnant prior to screening
  • History of bilateral adrenalectomy, hypopituitarism, or other condition requiring chronic GC therapy
  • History of cancer excluding cured/treated dermal squamous or basal cell carcinoma or cervical carcinoma in situ
  • Known history of, or concern for, risk of hypersensitivity reaction to atumelnant or any of its excipients
  • Participants with an increased risk of developing adrenal insufficiency as judged by the Investigator
  • Clinically significant medical condition or abnormal laboratory tests, as judged by the Investigator, other than CAH
  • Diagnosis of any form of CAH other than classic 21-OHD
  • Women who are pregnant or lactating or, if of childbearing potential, who are unwilling to use highly effective contraception as described in this study. Male participants who are unwilling to use highly effective contraception as described in this study
  • Severe erythrocytosis as judged by the Investigator

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 74 years old?

Where in United States

Also in 14 other countries, 63 sites

  • Ann Arbor, MichiganHospital not named in the registryContact: Crinetics Clinical TrialsTaking people
  • Atlanta, GeorgiaHospital not named in the registryContact: Crinetics Clinical TrialsTaking people
  • Aurora, ColoradoHospital not named in the registryContact: Crinetics Clinical TrialsTaking people
  • Baltimore, MarylandHospital not named in the registryContact: Crinetics Clinical TrialsTaking people
  • Charlottesville, VirginiaHospital not named in the registryContact: Crinetics Clinical TrialsTaking people
  • Chicago, IllinoisHospital not named in the registryContact: Crinetics Clinical TrialsTaking people
  • Dallas, TexasHospital not named in the registryContact: Crinetics Clinical TrialsTaking people
  • Gainesville, FloridaHospital not named in the registryContact: Crinetics Clinical TrialsTaking people
  • Los Angeles, CaliforniaHospital not named in the registryContact: Crinetics Clinical TrialsTaking people
  • Milwaukee, WisconsinHospital not named in the registryContact: Crinetics Clinical TrialsTaking people
  • Minneapolis, MinnesotaHospital not named in the registryContact: Crinetics Clinical TrialsTaking people
  • New Brunswick, New JerseyHospital not named in the registryContact: Crinetics Clinical TrialsTaking people
  • Philadelphia, PennsylvaniaHospital not named in the registryContact: Crinetics Clinical TrialsTaking people
  • Pittsburgh, PennsylvaniaHospital not named in the registryContact: Crinetics Clinical TrialsTaking people
  • Rochester, MinnesotaHospital not named in the registryContact: Crinetics Clinical TrialsTaking people

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the efficacy, safety, PK, and PD of atumelnant in adults with classic CAH due to 21-OHD.

The 2 groups in the trial

  • TreatmentTreatment being tested

    Atumelnant tablet, administered orally, once daily for 32 weeks.

    Treatment: Atumelnant

  • PlaceboPlacebo, for comparison

    Matching placebo, administered orally, once daily for 32 weeks.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atumelnant in Adult Participants With Classic Congenital Adrenal Hyperplasia (Calm-CAH)
Criteria questions
Built from NCT07144163, who can take part
Record updated
10 November 2026